Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + melphalan conditioning before autologous HSCT for multiple myeloma
ChiCTR2100047782Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine and melphalan in multiple myeloma (MM), sponsored by West China Hospital of Sichuan University. Primary endpoint: complete remission rate. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
bendamustinemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100047782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047782.